Advertisement

Topics

The phenylthiourea is a competitive inhibitor of the enzymatic oxidation of DOPA by phenoloxidase.

06:00 EDT 4th May 2011 | BioPortfolio

Summary of "The phenylthiourea is a competitive inhibitor of the enzymatic oxidation of DOPA by phenoloxidase."

Phenoloxidase is a key enzyme of melanization catalyzing the oxidation of phenols. Phenylthiourea (PTU) is the well-known and widely used inhibitor of phenoloxidase. However, the mechanism of its action is not quite clear. In the present work, the effect of PTU on the enzymatic oxidation of 3-(3,4-dihydroxyphenyl)-l-alanine (DOPA) by phenoloxidase was studied by spectrophotometric methods. The inhibition constant of PTU was estimated as 0.21 ± 0.09 µM and the competitive type of inhibition was determined for this reaction.

Affiliation

Institute of Chemical Kinetics and Combustion, Laboratory of Chemistry and Physics of Free Radicals, Institutskaya 3, Novosibirsk, Russian Federation.

Journal Details

This article was published in the following journal.

Name: Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Pages:

Links

DeepDyve research library

PubMed Articles [6788 Associated PubMed Articles listed on BioPortfolio]

α,β-Dehydro-Dopa: a hidden participant in mussel adhesion.

Dopa (L-3,4-dihydroxyphenylalanine) is a key chemical signature of mussel adhesive proteins, but its susceptibility to oxidation has limited mechanistic investigations as well as practical translation...

Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.

Tyrosinase catalyzes two distinct sequential reactions in melanin biosynthesis: the hydroxylation of tyrosine to DOPA followed by the oxidation of DOPA to dopaquinone. The central roles of melanin in ...

Purification, Characterization and Biological Activity of Polysaccharides from Dendrobium officinale.

Polysaccharide (DOPA) from the stem of D. officinale, as well as two fractions (DOPA-1 and DOPA-2) of it, were isolated and purified by DEAE cellulose-52 and Sephacryl S-300 chromatography, and their ...

L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.

Dopamine replacement therapy by its precursor, L-3.4-Dihydroxyphenylalanine (L-DOPA), has been the treatment of choice for Parkinson's disease. However, the possible contributory effect of L-DOPA ther...

Improved Flux of Levodopa via Direct Deposition of Solid Microparticles on Nasal Tissue.

Epithelial flux and permeability across bovine olfactory tissue were compared when levodopa (L-DOPA) was loaded in different physical states. Aqueous solution of L-DOPA was prepared in Krebs-Ringer bu...

Clinical Trials [1718 Associated Clinical Trials listed on BioPortfolio]

Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)

Imaging of neuroendocrine (NETs), such as carcinoids and pheochromocytomas (PHEOs), is suboptimal, limiting curative treatment. The investigators wanted to explore the use of PET and F-DOP...

Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer

Medullary thyroid carcinoma (MTC) is a rare tumor arising from C cells of the thyroid gland and belonging to the endocrine tumors. 18F-DOPA PET, based on tha capacity of endocrine tumor ce...

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

This Phase IIb exploratory study is designed to determine whether AFQ056 is safe and effective and whether it can increase the therapeutic window of L-dopa in patients whose control of the...

Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)

The purpose of this study is to investigate a new use for a medication called levodopa (L-DOPA). L-DOPA has been approved for use in Parkinson 's disease, but not for Posttraumatic Stress ...

Study of Protein Translocation in Patients With Beta-Oxidation Disorders

OBJECTIVES: I. Characterize inheritance patterns of mutations in patients with beta-oxidation disorders.

Medical and Biotech [MESH] Definitions

One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of dopa to dopamine. It is of clinical importance in the treatment of Parkinson's disease. EC 4.1.1.28.

Isoprostanes derived from the free radical oxidation of ARACHIDONIC ACID. Although similar in structure to enzymatically synthesized prostaglandin F2alpha (DINOPROST), they occur through non-enzymatic oxidation of cell membrane lipids.

An enzyme of the oxidoreductase class that catalyzes the reaction between L-tyrosine, L-dopa, and oxygen to yield L-dopa, dopaquinone, and water. It is a copper protein that acts also on catechols, catalyzing some of the same reactions as CATECHOL OXIDASE. EC 1.14.18.1.

A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed)

An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.

Quick Search
Advertisement
 


DeepDyve research library

Relevant Topic

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...